checkAd

    DGAP-News  386  0 Kommentare EVOTEC AND FORGE THERAPEUTICS FORM STRATEGIC 'SUPERBUG' ALLIANCE

    DGAP-News: Evotec AG / Key word(s): Alliance
    EVOTEC AND FORGE THERAPEUTICS FORM STRATEGIC 'SUPERBUG' ALLIANCE

    09.12.2016 / 07:30
    The issuer is solely responsible for the content of this announcement.

    ---------------------------------------------------------------------------

    Anzeige 
    Handeln Sie Ihre Einschätzung zu Evotec SE!
    Long
    13,43€
    Basispreis
    1,37
    Ask
    × 10,53
    Hebel
    Short
    15,75€
    Basispreis
    1,42
    Ask
    × 10,34
    Hebel
    Präsentiert von

    Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

    * Combination of leading innovative chemistry efforts with cutting-edge
    anti-infective drug discovery platform

    Hamburg, Germany, 09 December 2016:
    Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today
    announced a strategic alliance with Forge Therapeutics, Inc. ("Forge") to
    advance its novel Gram-negative antibiotic programme targeting 'LpxC' for
    the treatment of bacterial infections including those caused by drug
    resistant 'superbugs'. LpxC has been recognised as an attractive
    antibacterial target for more than the past 15 years; however, a lack of
    suitable chemical starting points has hampered its progress. Forge has been
    applying its proprietary metal-binding pharmacophores ("MBP") library and
    processes and has been able to identify potent drugable inhibitors of LpxC.

    The alliance will be focused on lead optimisation of these inhibitors with
    the goal of identifying a development candidate in the next couple of years
    Evotec will, through a team of more than 10 scientists, contribute
    cutting-edge biochemistry, microbiology, medicinal chemistry, structural
    biology, computational chemistry, ADME/PK/analytical, and programme
    management.

    "Antibacterials that act via novel mechanisms of action are desperately
    needed to address untreatable infections that arise from drug-resistant
    Gram-negative bacteria", said Zachary A. Zimmerman, Ph.D., CEO of Forge
    Therapeutics. "Our LpxC inhibitors have proven to be stable, potent in
    vitro, and have shown preliminary efficacy in vivo. We are thrilled to
    partner with Evotec during lead optimisation as they provide significant
    pre-clinical expertise and added horsepower to rapidly advance our novel
    antibiotic to address this growing unmet global issue."

    "The antibiotic field has been suffering from an innovation void over the
    last 30 years and requires significant intellectual and financial stimulus
    to address the issues of resistance", said Dr Mario Polywka, Chief
    Operating Officer of Evotec. "Importantly, Forge's novel LpxC programme
    coupled with Evotec's unrivalled drug discovery platform and expertise
    offers significant promise in addressing this issue. We look forward to
    working with our new partners at Forge."


    ABOUT LPXC
    LpxC is conserved across Gram-negative bacteria and not found in
    Gram-positive bacteria or human cells. Other LpxC inhibitors have been
    evaluated by biopharma in the past but chemistry limitations (e.g.
    Seite 1 von 3


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    DGAP-News EVOTEC AND FORGE THERAPEUTICS FORM STRATEGIC 'SUPERBUG' ALLIANCE DGAP-News: Evotec AG / Key word(s): Alliance EVOTEC AND FORGE THERAPEUTICS FORM STRATEGIC 'SUPERBUG' ALLIANCE 09.12.2016 / 07:30 The issuer is solely responsible for the content of this announcement. …

    Schreibe Deinen Kommentar

    Disclaimer